 OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to HLA-type HLA-A1 positive vs HLA-A2 positive, HLA-A1 negative, or -A3 negative vs HLA-A3 positive, or -A1 negative and participating center University of Virginia UVA vs non-UVA. Patients are randomized to 1 of 4 treatment arms. 